Previsioni

Acquista	5
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

BioVie shareholders confirm board candidates and expand equity plan

At the annual general meeting, BioVie shareholders approved all six nominated directors for one year and confirmed EisnerAmper as independent auditors for the fiscal year ending June 30, 2026. The "2019 Omnibus Equity Incentive Plan" was restated and the number of shares authorized for issuance was increased to 3,100,000. A total of 3,417,857 Class A common shares were represented at the vote; numerous broker non‑votes were reported. » Altro su de.investing.com
BioVie reports quarterly loss per share of $1.42

BioVie presented results for the quarter ended June 30, 2025, and reported a loss per share of $1.42 (prior year: -$3,000). For the full year, a loss per share of $12,120 was reported (prior year: -$73,000). » Altro su finanzen.net
Biovie shares drop 43% after pricing of $12 million offering

Biovie Inc plunged 43% after the company priced a firm-commitment public offering of $12 million, consisting of 6 million units at $2.00 per unit. Each unit comprises one common share and one warrant; the warrants are exercisable at $2.50 per share, proceeds will be used for working capital and general corporate purposes, and ThinkEquity is acting as sole bookrunner. Closing is expected on August 11, 2025; the warrants included in the offering are expected to begin trading on the Nasdaq Capital Market under the symbol BIVIW on August 8, 2025; there is also a 45-day over-allotment option. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, BIOVIE INC. DL-,0001 ha registrato ricavi pari a 0 € e un utile netto di -4,95 Mln €

(EUR)	giu 2026	YoY
Ricavi	0	-
Utile lordo	-5,53K	88,64%
Utile netto	-4,95 Mln	67,10%
EBITDA	-5,01 Mln	72,18%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	13,74 Mln €
Numero di azioni	7,54 Mln
Massimo/minimo a 52 settimane	3,27 € - 0,71 €
Dividendi	No
Beta	0,67
Rapporto P/E	-0,66
Rapporto PEG	-0,01
Rapporto P/B	1,55
Rapporto P/S	0,00

Profilo aziendale

BioVie Inc. ist ein Biotechnologieunternehmen im klinischen Stadium, das sich mit der Entdeckung, Entwicklung und Vermarktung von Arzneimitteltherapien in den Vereinigten Staaten befasst. Zu den Produkten in der Pipeline gehören BIV201, das eine klinische Studie der Phase IIa zur Behandlung von Aszites bei chronischer Leberzirrhose abgeschlossen hat, und NE3107, das sich in einer klinischen Studie der Phase III zur Behandlung von Patienten mit leichter bis mittelschwerer Alzheimer-Krankheit und einer klinischen Studie der Phase I zur Behandlung der Parkinson-Krankheit befindet. Das Unternehmen entwickelt außerdem NE3107, das sich in der präklinischen Phase für die Behandlung von multiplem Myelom und Prostatakrebs befindet. Das Unternehmen war früher unter dem Namen NanoAntibiotics, Inc. bekannt und änderte im Juli 2016 seinen Namen in BioVie Inc. BioVie Inc. wurde im Jahr 2013 gegründet und hat seinen Sitz in Carson City, Nevada.

Nome	BIOVIE INC. DL-,0001
CEO	Cuong Viet Do
Sede centrale	Carson City, nv Stati Uniti
Sito web	bioviepharma.com
Settore	Materiali
Industria	Prodotti chimici
Quotazione in borsa	18/09/2020
Dipendenti	13